Search

Search Constraints

You searched for: Author/Creator Kalff, Anna

Search Results

2. A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16‐02 trial. (15th May 2021)

3. Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. Issue 8 (August 2017)

4. Central nervous system multiple myeloma – potential roles for intrathecal therapy and measurement of cerebrospinal fluid light chains. (29th May 2013)

5. Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD). Issue 12 (15th October 2021)

7. Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia. Issue 10 (18th October 2021)

8. Oral azacitidine (CC-486) in combination with lenalidomide and dexamethasone in advanced, lenalidomide-refractory multiple myeloma (ROAR study). Issue 9 (29th July 2019)

9. Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study. Issue 9 (29th July 2019)

10. Phase II trial of single‐agent panobinostat consolidation improves responses after sub‐optimal transplant outcomes in multiple myeloma. (18th September 2020)